Overview

A class action lawsuit has been filed against Organon & Co. (“Organon” or the “Company”) and certain of the Company’s former directors and chief executive officers alleging violations of the federal securities laws. Organon & Co’s common stock trades on the New York Stock Exchange (the “NYSE”) under the symbol “OGN.”

The Organon & Co class action lawsuit was brought on behalf of all persons and entities who purchased or otherwise acquired Organon securities between October 31, 2024, to April 30, 2025, inclusive (the “Class Period”).

Organon is a global healthcare company with a primary focus on improving the health of women throughout their lives. The Company develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women’s health, biosimilars and established brands. Organon operates six manufacturing facilities, which are located in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the United Kingdom.

The Organon class action lawsuit alleges that Defendants, throughout the class period, provided investors with material information concerning Organon’s prioritization of its capital allocation strategy through regular, quarterly dividends. Defendants’ statements included, among other things, reassurance that capital allocation through the dividends was a #1 capital allocation priority and that Organon was committed to consistent deployment of capital.

Defendants provided these overwhelmingly positive statements to investors while, at the same time, disseminating materially false statements and/or concealing material adverse facts concerning the true state of the Company’s priorities, particularly, related to capital allocation through quarterly dividends. Notably, Defendants concealed the high priority of Organon’s debt reduction strategy following the Company’s acquisition of Dermavant, resulting in a 70% decrease for the regular quarterly dividend. Such statements absent these material facts caused Plaintiff and other shareholders to purchase Organon’s securities at artificially inflated prices.

*          *          *

If you purchased or otherwise acquired Organon securities between October 31, 2024, and April 30, 2025, both dates inclusive, and you wish to serve as lead plaintiff in this lawsuit, we encourage you to submit your information to DiCello Levitt LLP via the form on this page. 

You can also contact DiCello Levitt partner Brian O’Mara by calling (888) 287-9005 or at [email protected]. 

The deadline to apply to the Court to serve as lead plaintiff in the Organon class action lawsuit is July 22, 2025.